Valeant (VRX) volatility flat into upgrade to Overweight at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
RBC Capital Remains Sidelined as Valeant Pharma (VRX) Announces Credit Amendment
August 18, 2016 11:15 AM EDTRBC Capital reiterated a Sector Perform rating and $36.00 price target on Valeant Pharmaceuticals (NYSE: VRX) following the company's announcement that is has agreed to amend terms with its lenders. This decision comes on the heels of VRX's Aug 12th announcement that the company would... More
Valeant Pharma (VRX) Ramps to Session Highs Following Analyst Upgrade
August 17, 2016 12:00 PM EDTValeant Pharma (NYSE: VRX) shares are reaching new session highs midday Wednesday. The stock is up well over 13 percent with high volume.
Notably, Morgan Stanley upgraded the stock earlier. For more color on the call, click here.
... More